Fda approves first oral wegovy pill for weight loss, expanding novo nordisk’s glp-1 lineup

FDA approves first oral Wegovy pill for weight loss, expanding Novo Nordisk’s GLP-1 lineup

Posted by
1 min read
December 27, 2025

PLAINSBORO, N.J. — The U.S. Food and Drug Administration has approved Novo Nordisk’s Wegovy® pill, making it the first and only oral GLP-1 medication cleared for chronic weight management in adults, the company announced Monday.

The once-daily semaglutide 25 mg tablet is designed to be used alongside reduced-calorie diets and increased physical activity for adults with obesity or overweight with weight-related medical conditions. It also becomes the only GLP-1 treatment indicated to reduce the risk of major cardiovascular events—including death, heart attack, or stroke—in adults with overweight or obesity and established cardiovascular disease.

“The launch of Wegovy in 2021 changed how obesity was viewed and treated in the U.S.,” said Dave Moore, executive vice president of U.S. Operations at Novo Nordisk. “Now, with Wegovy pill, we’re offering a magnitude of weight loss that no other oral GLP-1 obesity candidate has been able to duplicate in phase 3 trials.”

The FDA approval is supported by data from the OASIS 4 phase 3 clinical trial, which studied 307 adults with obesity or overweight without diabetes over 64 weeks. Results showed that patients taking Wegovy tablets lost an average of about 17% of their body weight if they remained on treatment, compared to about 3% with placebo. When factoring in all participants regardless of adherence, average weight loss was about 14% with Wegovy versus 2% with placebo.

Novo Nordisk said the Wegovy pill will launch nationwide in early January 2026 with a starting dose of 1.5 mg priced at $149 per month through savings offers. The medication is being manufactured in North Carolina with what the company described as a “robust supply” already on hand.

Since its initial approval as an injectable treatment in 2021, Wegovy has been prescribed to approximately 3.2 million people in the U.S., according to Novo Nordisk. The pill marks a major step in the company’s expansion of its GLP-1 portfolio, a class of drugs that has reshaped obesity and diabetes treatment worldwide.

The FDA’s approval of Novo Nordisk’s Wegovy pill introduces the first oral GLP-1 therapy for weight loss and cardiovascular protection in U.S. adults.

Phil Stilton

Phil Stilton is the Editor and Publisher of Shore News Network, an independent digital newsroom providing original reporting on New Jersey, national news, government, public policy, public safety, courts, and community affairs.

As founder of the publication, Stilton leads editorial strategy, investigative reporting, and daily newsroom operations while overseeing coverage that reaches millions of readers annually.

With extensive experience covering municipal government, county government, state legislatures, elections, law enforcement, emergency management, and public records, Stilton specializes in translating complex government actions into clear, factual reporting. His work frequently relies on primary source documents, including court filings, legislation, public meeting records, election finance disclosures, government databases, police reports, and Freedom of Information and Open Public Records Act (OPRA) requests. He has reported extensively on local government accountability, taxpayer spending, campaign finance, public corruption investigations, infrastructure, public safety, and the policies affecting New Jersey residents.

Under Stilton's editorial leadership, Shore News Network has grown into one of New Jersey's largest independent digital news organizations, publishing thousands of original news articles each year while providing breaking news coverage, investigative reporting, and analysis across state and local government. The publication's reporting is routinely sourced from official government agencies, public officials, court records, and firsthand documentation, with a commitment to transparency, attribution, corrections when warranted, and clearly distinguishing factual reporting from opinion.

Stilton's journalism follows established newsroom standards emphasizing accuracy, verification, fairness, and accountability. Every effort is made to verify information through official records and multiple reliable sources before publication. His reporting is intended to provide readers with timely, well-documented information that helps them understand the issues affecting their communities, while maintaining editorial independence from political parties, government agencies, advocacy organizations, and commercial interests.

Readers can submit story tips, corrections, public records, or media inquiries through the official Shore News Network website or its verified social media channels. Shore News Network welcomes corrections and updates when new information becomes available as part of its ongoing commitment to accurate and transparent journalism.

Shore News Network

Follow us for real-time news updates across New Jersey.

Related news